CardioGenics Holdings (CardioGenics Holdings) Change In Working Capital : $0.28 Mil (TTM As of Jan. 2016)

View and export this data going back to 2004. Start your Free Trial

What is CardioGenics Holdings Change In Working Capital?

CardioGenics Holdings's change in working capital for the quarter that ended in Jan. 2016 was $0.09 Mil.

CardioGenics Holdings's change in working capital for the fiscal year that ended in Oct. 2015 was $0.23 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

CardioGenics Holdings Change In Working Capital Historical Data

The historical data trend for CardioGenics Holdings's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardioGenics Holdings Change In Working Capital Chart

CardioGenics Holdings Annual Data

Trend

Jul06

Jul07

Jul08

Oct09

Oct10

Oct11

Oct12

Oct13

Oct14

Oct15

Change In Working Capital

Get a 7-Day Free Trial

0.17

0.30

0.48

0.25

0.23

CardioGenics Holdings Quarterly Data
	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13	Jan14	Apr14	Jul14	Oct14	Jan15	Apr15	Jul15	Oct15	Jan16
Change In Working Capital	Get a 7-Day Free Trial															0.04	-	-0.01	0.19	0.09

CardioGenics Holdings Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jan. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.28 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

CardioGenics Holdings Change In Working Capital Related Terms

Thank you for viewing the detailed overview of CardioGenics Holdings's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

CardioGenics Holdings (CardioGenics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CardioGenics Holdings Inc (OTCPK:CGNH) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

6295 Northam Drive, Unit 8, Mississauga, ON, CAN, L4V 1W8

Website

http://www.cardiogenics.com

CardioGenics Holdings Inc is a biotechnology company. It is engaged in the development and commercialization of diagnostic test products for the In-Vitro Diagnostics (IVD) testing market. The company's objective is to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies. Its products include QL Care Analyzer, Immunoassay Tests, and Paramagnetic Beads. The business activity is primarily carried out through the region of Canada.

CardioGenics Holdings (CardioGenics Holdings) Headlines

No Headlines